Compare Merck & Co., Inc. (MRK) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $38.55. The key difference: Merck & Co., Inc. pays a 2.29% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MRK | QDTY | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $156.43 | $46.71 |
52-Week Low | $77.60 | $36.57 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
QDTY trades at $39.07, up 0.12% on the day, with a bearish technical signal driven by moving averages. The stock exhibits weekly dividend distributions, yet key valuation and profitability ratios are unavailable, limiting fundamental clarity. Recent news highlights consistent dividend announcements from YieldMax ETFs, indicating a focus on income generation.
The outlook hinges on forthcoming financial disclosures to assess sustainability; risks include reliance on dividend strategy amid missing fundamentals. Investors face uncertainty without earnings or revenue data, requiring caution until corporate performance metrics are published.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
